Name | Ibutamoren mesylate |
Synonyms | MK677 MK-677 MK 677 MK 0677 MK0677 CS-1402 MK-0677 MK 0677 MK-0677 CRESCENDO MK677,Mk677 MK677 POWDER MK 677 IBUTAMOREN Ibutamoren mesylate MK677 MK 677 IBUTAMOREN MK677(Ibutamoren Mesylate) mk677 mk 677 Ibutamoren,whnohe_lucy(at)163.com 2-Amino-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methylpropanamide methanesulfonate |
CAS | 159752-10-0 |
EINECS | 1308068-626-2 |
InChI | InChIKey DUGMCDWNXXFHDE-VZYDHVRKSA-N |
InChIKey | DUGMCDWNXXFHDE-VZYDHVRKSA-N |
Molecular Formula | C28H40N4O8S2 |
Molar Mass | 624.77 |
Melting Point | 164-170°C |
Solubility | 10 mM in DMSO |
Appearance | powder |
Color | white to beige |
Storage Condition | 2-8°C |
Use | Ibrutam mesylate is a drug that acts as a potent, orally effective somatotropin secretion, mimicking the action of gh to stimulate endogenous hormones. |
In vivo study | Ibutamoren mesylate (5 mg/kg/day) results in a statistically significant increases body weight gain and increases serum IGF-1 and GH levels in dogs. Ibutamoren mesylate results in no significant increase in CSF IGF-1 or GH levels on days 7 or 15 of the study. Pretreating mice with GH blocks activation of these neurons by Ibutamoren mesylate (50 μg, i.p.). In the knockout mice, both GH and octreotide fail to inhibit Ibutamoren mesylate activation of arcuate neurons. Chronic oral administration of MK-0677 is associated with significant increases in GH and IGF-I levels that are maintained for the duration of the treatment. The GH profile following MK-0677 administration consists of episodic increases above control. MK-0677 significantly increases peak GH concentrations after oral administration. MK-0677 is a potent GH secretagogue that induces an immediate, large, long lasting increase in GH levels when administered orally or i.v. |
WGK Germany | 3 |
RTECS | TX1404490 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.601 ml | 8.003 ml | 16.006 ml |
5 mM | 0.32 ml | 1.601 ml | 3.201 ml |
10 mM | 0.16 ml | 0.8 ml | 1.601 ml |
5 mM | 0.032 ml | 0.16 ml | 0.32 ml |
storage conditions | 2-8°C |
solubility | H2O: soluble5mg/mL, clear |
morphology | powder |
color | white to beige |
InChIKey | DUGMCDWNXXFHDE-VZYDHVRKSA-N |
product description | immolenmethanesulfonate is a drug that acts as a powerful, orally effective growth-stimulating hormone secretion, mimicking the effect of gh on stimulating endogenous hormones. |
Effect | Ibmoren mesylate has been proven to increase the release and produce continuous increase Some hormones in plasma levels include gh and insulin-like growth factor 1 (igf-1), but do not affect cortisol levels. Potential treatments currently being developed reduce the levels of these hormones, such as in children or the elderly with growth hormone deficiency, and human studies have shown increased muscle and bone mineral density, making it a promising treatment for the frail elderly. It also changes the metabolism of body fat, so it may be used in the treatment of obesity. |
drug action | MK-677(l-163191) is a drug that acts as a powerful, orally effective growth-promoting hormone secretion, mimicking the effect of GH stimulating endogenous hormones. it has been proved to increase the release and produce some hormones that continuously increase plasma levels, including GH and insulin-like growth factor 1 (igf-1), but does not affect cortisol levels. |
biological activity | Ibutamoren mesylate (MK-0667, L-163191) is an orally effective growth hormone (GH) secretagogue and an effective non-peptide ghrelin receptor agonist. |
in vivo study | Ibutamoren mesylate (5 mg/kg/day) results in a statistically significant increases body weight gain and increases series IGF-1 and GH levels in dogs. Ibutamoren mesylate results in no significant increase in CSF IGF-1 or GH levels on days 7 or 15 of the study. Pretreating mice with GH blocks activation of these neurons by Ibutamoren mesylate (50 μ g, I. p.). in the knockout mice, both GH and octreotide fail to inhibit Ibutamoren mesylate activation of arcuate neurons. Chronic oral administration of MK-0677 is associated with significant increases in GH and IGF-I levels that are maintained for the duration of the treatment. The GH profile following MK-0677 administration consists of episodic increases above control. MK-0677 significantly increases peak GH concentrations after oral administration. MK-0677 is a potent GH secretagogue that induces an immediate, large, long lasting increase in GH levels when administered orally or I. v. |